The potential for targeting HER2 therapeutically in esophageal cancer – a grasp at straws?

Bibliography

• Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008;100(16):1184-7
   PubMed Web of Science ®Google Scholar
• Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007;26(45):6469-87
   PubMed Web of Science ®Google Scholar
• Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer drugs 2012;23(8):765-76
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97
   PubMed Web of Science ®Google Scholar
• Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984;312(5994):513-16
   PubMed Web of Science ®Google Scholar
• King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985;229(4717):974-6
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986;319(6050):230-4
   PubMed Web of Science ®Google Scholar
• Yokota J, Yamamoto T, Toyoshima K, et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1986;1(8484):765-7
   PubMed Web of Science ®Google Scholar
• Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230(4730):1132-9
   PubMed Web of Science ®Google Scholar
• Olayioye MA. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res 2001;3(6):385-9
   PubMed Web of Science ®Google Scholar
• Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(Suppl 4):S3-8
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2(2):127-37
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421(6924):756-60
   PubMed Web of Science ®Google Scholar
• Penault-Llorca F, Chenard MP, Bouche O, et al. [HER2 and gastric cancer. Recommendations for clinical practice in 2011]. Ann Pathol 2011;31(2):78-87
   Google Scholar
• Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52(7):797-805
   PubMed Web of Science ®Google Scholar
• Grillo F, Fassan M, Ceccaroli C, et al. The reliability of endoscopic biopsies in assessing HER2 status in gastric and gastroesophageal junction cancer: a study comparing biopsies with surgical samples. Transl Oncol 2013;6(1):10-16
   Google Scholar
• Watson S, Validire P, Cervera P, et al. Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. Ann Oncol 2013;24(12):3035-9
   PubMed Web of Science ®Google Scholar
• Fassan M, Ludwig K, Pizzi M, et al. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Hum Pathol 2012;43(8):1206-12
   Google Scholar
• Schoppmann SF, Jesch B, Zacherl J, et al. HER-2 status in primary oesophageal cancer, lymph nodes and distant metastases. Br J Surg 2011;98(10):1408-13
   PubMed Web of Science ®Google Scholar
• Konig AM, Reeh M, Dancau AM, et al. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma. Anticancer Res 2013;33(11):4975-82
   PubMed Web of Science ®Google Scholar
• Gowryshankar A, Nagaraja V, Eslick GD. HER2 status in Barrett’s esophagus & esophageal cancer: a meta analysis. J Gastrointest Oncol 2014;5(1):25-35
   Google Scholar
• Kono K, Mimura K, Fujii H, et al. Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma. Ann Thorac Cardiovasc Surg 2012;18(6):506-13
   Google Scholar
• Yoon HH, Shi Q, Sukov WR, et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 2012;18(2):546-54
   PubMed Web of Science ®Google Scholar
• Gordon MA, Gundacker HM, Benedetti J, et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 2013;24(7):1754-61
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012;23(10):2656-62
   PubMed Web of Science ®Google Scholar
• Thompson SK, Sullivan TR, Davies R, et al. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol 2011;18(7):2010-17
   PubMed Web of Science ®Google Scholar
• Phillips BE, Tubbs RR, Rice TW, et al. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction. Dis Esophagus 2013;26(3):299-304
   Web of Science ®Google Scholar
• Chan DS, Twine CP, Lewis WG. Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. J Gastrointest Surg 2012;16(10):1821-9
   PubMed Web of Science ®Google Scholar
• Akamatsu M, Matsumoto T, Oka K, et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2003;57(5):1323-7
   PubMed Web of Science ®Google Scholar
• Dreilich M, Wanders A, Brattstrom D, et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus 2006;19(4):224-31
   PubMed Web of Science ®Google Scholar
• Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345(10):725-30
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007;357(1):39-51
   PubMed Web of Science ®Google Scholar
• Gros SJ, Kurschat N, Dohrmann T, et al. Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma. Mol Cancer Ther 2010;9(7):2037-45
   Google Scholar
• Lange T, Nentwich MF, Luth M, et al. Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma. Cancer Lett 2011;308(1):54-61
   Google Scholar
• van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366(22):2074-84
   PubMed Web of Science ®Google Scholar
• Safran H, Dipetrillo T, Akerman P, et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;67(2):405-9
   PubMed Web of Science ®Google Scholar
• Kordes S, Cats A, Meijer SL, et al. Targeted therapy for advanced esophagogastric adenocarcinoma. Crit Rev Oncol Hematol 2014;90(1):68-76
   Google Scholar
• Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009;27(34):5838-47
   PubMed Web of Science ®Google Scholar